Get the Daily Brief
Latest Biotech News
Long‑acting injectable buprenorphine reduces inpatient service use
A recent study reported that long‑acting injectable formulations of buprenorphine significantly lowered the need for inpatient care among patients with opioid use disorder. Researchers documented...
3D‑printed glioblastoma scaffolds and COX‑2 target reshape therapy testing
Two independent reports advance glioblastoma research from complementary angles: a 3D‑printed scaffold model that better replicates tumor microarchitecture for drug screening, and a separate study...
Mapping metabolic liver disease in India — new population signals
Two pieces examining metabolic dysfunction‑associated steatotic liver disease (MASLD) in Indian cohorts highlight rising prevalence and heterogeneous demographic risk. A letter and a mapping study...
Glycation accelerates alpha‑synuclein aggregation and neuroinflammation in Parkinson’s
Twin publications in npj Parkinson’s Disease report that protein glycation increases alpha‑synuclein aggregation and heightens neuroinflammatory responses in models relevant to Parkinson’s...
Wastewater rotavirus RNA reflects US infection and vaccination patterns
Researchers demonstrated that rotavirus RNA levels in wastewater correlate with regional infection prevalence and vaccination coverage across the United States. The study positions...
Biogen buys Vanqua C5aR1 program: $70M up front, $990M in milestones
Biogen announced an exclusive worldwide license to Vanqua Bio’s preclinical C5aR1 inhibitor, paying $70 million up front with up to $990 million in contingent payments. The deal hands Biogen...
Two nonhormonal menopause drugs win FDA nod — Bayer’s Lynkuet, elinzanetant
The FDA cleared Bayer’s Lynkuet for treatment of menopause-related hot flashes and separately approved elinzanetant as a nonhormonal option for vasomotor symptoms. Bayer said Lynkuet is the first...
Gepotidacin... approved for UTIs; gonorrhea filing remains active
Gepotidacin, a novel oral inhibitor of bacterial type II topoisomerases, received approval in March 2025 for uncomplicated urinary tract infections under the brand Blujepa and is under FDA review...
Halda posts first RIPTAC clinical data: prostate responses emerge
Halda Therapeutics released initial clinical readouts from an ongoing study of its RIPTAC platform in prostate cancer, reporting early signals of activity. The company described a first cut of...
Tetraneuron advances AAV gene therapy: targets E2F4 to restore memory
Spanish biotech Tetraneuron presented an upstream gene‑therapy approach—TET‑101—using AAV to modulate the transcription factor E2F4, aiming to halt neuronal cell‑cycle reentry and restore memory...
Nanopore pinpoints tissue‑of‑origin and pathogens in plasma cfDNA
Researchers deployed nanopore sequencing on plasma cell‑free DNA from critically ill patients to capture simultaneous tissue‑of‑origin signals and detect pathogenic DNA. The study demonstrated...
FDA flags unauthorized Indian API warehouse — lizards, cats found
The FDA issued an inspection report revealing an unauthorized warehouse in India holding active pharmaceutical ingredients and finished drugs that was reportedly infested with lizards and cats....
Metagenomic hunt uncovers retron editors — new gene‑editing candidates
Scientists screened bacterial and archaeal metagenomes to identify, test and begin improving retron‑based self‑priming gene editors compatible with Cas enzymes. The work yielded candidate retrons...
UCSD engineers yeast: cross‑organelle tweaks boost plant‑compound yields
A UC San Diego team reported methods to improve yeast performance as biofactories for complex plant compounds by optimizing cytochrome P450 function and coordinating metabolic activity across...
VCs spin Teijin program into Elevara — finance report
Investors Weatherden and venture capital partners spun Teijin’s internal program into a new company, Elevara, in a financing move covered by BioCentury. The transaction includes seed financing and...
Biogen licenses Vanqua C5aR1 program: $70M upfront, nearly $1B in milestones
Biogen struck an exclusive global licensing deal for Vanqua Bio’s preclinical C5aR1 inhibitor, paying $70 million up front with up to $990 million in development, regulatory and commercial...
Lilly to acquire Adverum: upfront below last close, gene‑therapy assets included
Eli Lilly agreed to acquire Adverum in a deal that moves gene‑therapy assets and programs into Lilly’s pipeline amid a tough market for standalone gene‑therapy developers. The transaction price...
FDA greenlights new menopause options: nonhormonal therapies expand clinical choices
Two recent U.S. regulatory actions broaden nonhormonal treatment options for menopausal vasomotor symptoms. The FDA approved elinzanetant, a nonhormonal agent shown in multinational trials to...
Inhibrx posts registrational win: ozekibart PFS gains spark BLA plans
Inhibrx reported that ozekibart (INBRX‑109) met the primary endpoint in a registrational phase II trial for advanced or metastatic unresectable chondrosarcoma, delivering statistically significant...
Halda unveils first RIPTAC clinical data: prostate study shows early activity
Halda Therapeutics disclosed initial clinical data from an ongoing study of its RIPTAC small‑molecule platform in prostate cancer, presenting the first human evidence of target engagement and...